TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07617324: A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Pharmacokinetics of Stapokibart Injection in Adolescent Patients With SAR Under Background Therapy

Sponsor: Chengdu Kangnuoxing Biopharma,Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$929,600

Rescue Site Savings

+$597,600

Unlock Full NCT07617324 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07617324 Rescue Dossier →